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ttp://dx.doi.org/10.1016/j.ajpath.2014.08.026Complement factor H (CFH) is an important regulatory protein in the alternative pathway of the
complement system, and CFH polymorphisms increase the genetic risk of age-related macular degen-
eration dramatically. These same human CFH variants have also been associated with dense deposit
disease. To mechanistically study the function of CFH in the pathogenesis of these diseases, we created
transgenic mouse lines using human CFH bacterial artiﬁcial chromosomes expressing full-length human
CFH variants and crossed these to Cfh knockout (Cfh/) mice. Human CFH protein inhibited cleavage of
mouse complement component 3 and factor B in plasma and in retinal pigment epithelium/choroid/
sclera, establishing that human CFH regulates activation of the mouse alternative pathway. One of the
mouse lines, which express relatively higher levels of CFH, demonstrated functional and structural
protection of the retina owing to the Cfh deletion. Impaired visual function, detected as a deﬁcit in the
scotopic electroretinographic response, was improved in this transgenic mouse line compared with
Cfh/ mice, and transgenics had a thicker outer nuclear layer and less suberetinal pigment epithelium
deposit accumulation. In addition, expression of human CFH also completely protected the mice from
developing kidney abnormalities associated with loss of CFH. These humanized CFH mice present a
valuable model for study of the molecular mechanisms of age-related macular degeneration and dense
deposit disease and for testing therapeutic targets. (Am J Pathol 2015, 185: 29e42; http://dx.doi.org/
10.1016/j.ajpath.2014.08.026)Supported by funding from NIH grants EY019038 (C.B.R.) and P30
EY005722, Edward N. & Della L. Thome Memorial Foundation Award
(C.B.R.), and the Foundation Fighting Blindness (C.B.R.).
Disclosure: None declared.Age-related macular degeneration (AMD) is a disease that
progressively damages the photoreceptors and retinal pigment
epithelium (RPE) in themacula, resulting in loss of vision in the
center of the visualﬁeld. AMD is the leading cause of blindness
in the elderly population, affecting approximately 15% of the
population older than 70 years of age.1,2 The earliest clinical
signs of AMD are pigmentary changes and the appearance of
drusen, focal protein- and lipid-rich extracellular deposits that
form between the RPE and the Bruch membrane (BrM). Late-
stage AMD is characterized by choroidal neovascularization,
geographic atrophy, or both, resulting in irreversible central
loss of the choriocapillaris, RPE, and photoreceptors.3e5
Abnormalities in dark adaptation are often the earlieststigative Pathology.
.functional change detected in patients with AMD and reﬂect
impairment of rod photoreceptor function.6,7
AMD is a complex disease inﬂuenced by a variety of
risk factors, including age, which is the greatest.8 Of the
genetic risk factors, a common polymorphism (T1277C) in
the complement factor H (CFH ) gene, resulting in a
tyrosine (Y) to histidine (H) substitution at amino acid 402
(H402), has been found to be strongly associated with the
Ding et aldevelopment of AMD.9e12 The same polymorphism has
also been linked to dense deposit disease (DDD, also
known as membranoproliferative glomerulonephritis type
II).13,14 DDD is a condition that primarily affects kidney
function. The symptoms usually appear between ages 5
and 15 years and include hematuria, proteinuria, and
nephrotic syndrome.15,16
CFH is a major regulator of the alternative pathway (AP) of
the complement system. The AP is initiated by complement
component 3 (C3) hydrolysis in which a C3 thioester interacts
with water to form C3(H2O). This occurs spontaneously and
causes the AP to be continuously active. Uninhibited,
C3(H2O) reacts with complement factor B (FB) to generate
C3(H2O)B, which in the presence of complement factor D is
converted to the C3 convertase C3(H2O)Bb. This conversion
allows for further cleavage of C3 to C3b and formation of the
C3bBb convertase and initiates the ampliﬁcation loop.
Without negative regulators, this positive feedback loop will
quickly deplete all available C3 in the system. CFH is the
soluble negative regulator of AP activation. CFH can inhibit
formation of the C3 convertase by competing with FB for
binding to C3b, accelerate decay of the C3 convertase, and act
as a cofactor for factor Iemediated cleavage of C3b.17
The complement system is important in defending an or-
ganism against foreign invasion by lyzing alien pathogens via
the formation ofmembrane attack complex and signaling debris
clearance. However, if dysregulated, the complement system
can also attack host cells, causing local inﬂammation and tissue
damage.18 Available data support the idea that in AMD, the AP
is dysregulated owing to CFH malfunction, causing local
inﬂammation and tissue damage in the macular region of the
retina. However, the cellular/molecular mechanism(s) for the
risk association of CFH in AMD pathogenesis remains unclear.
Consistent with a role for CFH in AMD pathogenesis, aged
mice lacking CFH (Cfh/) have an ocular phenotype that
shares characteristics of early AMD. These characteristics
include decreased electroretinogram (ERG) response, loss of
visual acuity, disrupted photoreceptor organization, and struc-
tural abnormalities of the BrM.19,20 These mice also sponta-
neously develop DDD-like pathologic abnormalities.21
To further elucidate the function of CFH in AMD patho-
genesis, we generated mice in which full-length human CFH
is expressed instead of mouse CFH. Using this mouse model,
we tested whether i) human CFH interacts with the mouse AP
of the complement system, ii) human CFH protein can rescueTable 1 Numbers of Mice Used for Each Class of Experiments
Genotype Real-time PCR Biochemistry IHC analysis ERG
C57 6 4 4
Cfh/ 6 3 6
CFH-Y:Cfh/ 3 9 3 11
CFH-H:Cfh/ 3 9 3 13
CFH-HH:Cfh/ 4
ERG, electroretinogram; IHC, immunohistochemical; TEM, transmission electron
30the ocular and renal phenotype in Cfh/ mice, and iii) there
are phenotypic differences between mice expressing the
normal Y402 or AMD riskeassociated H variant of CFH.
Materials and Methods
Generating Bacterial Artiﬁcial Chromosome Transgenic
Humanized CFH Mice
Mice were housed under normal lighting conditions with
12-hour on/off cycles. The care and treatment of animals
were strictly in accordance with the Institutional Animal
Care and Use Committee at Duke University (Durham, NC).
The bacterial artiﬁcial chromosome (BAC) clone RP11-
347L19 contains a 180-kb insert spanning the entire CFH
gene and two truncated ﬂanking genes (KCNT2 on the 50
side and CFHR3 on the 30 side). We conﬁrmed by
sequencing that the CFH gene codes for an H402 form of
CFH. To generate the Y402 variant of the humanized CFH
mice we used BAC clone CTD-2580H3, which has a 132-
kb insert in the region spanned by the H402 BAC (UCSC
Genome Browser). In collaboration with the Duke Neuro-
transgenic Laboratory, we generated founder transgenic
mice from these BAC clones containing the full-length
Y402 [Tg(CTD-2580H3)402Cbr, or CFH-Y mice for
short] and H402 [Tg(RP11-347L19)301Cbr, or CFH-H
mice for short] variants of the human CFH gene.
The founders were then crossed to C57Bl/6J (C57) mice
(The Jackson Laboratory, Bar Harbor, ME). Germline
transmission was conﬁrmed by analyzing the genomic DNA
of the offspring. Human CFH-positive N1 littermates were
bred to Cfh/ mice21 to generate the CFH-Y:Cfh/ and
CFH-H:Cfh/ mouse lines. Cfh/ mice on a C57 back-
ground were obtained from Dr. Glenn Jaffe (Durham, NC)
with an material transfer agreement from Imperial College
London and permission from Dr. Marina Botto (London,
UK). We maintained these two lines by crossing CFH:Cfh/
mice with Cfh/ mice. The Cfh/ littermates served as
controls. Animals used in this study were crossed to Cfh/
for more than six generations. We also mated CFH-H:Cfh/
mice together to generate a line of homozygous CFH-H
transgenic mice (CFH-HH:Cfh/), bearing in mind that this
might interrupt an endogenous gene important for normal
development.22 We conﬁrmed that none of the mice carry the
rd8 mutation.23Retina histology Retina TEM
Kidney histology
Aged 2 years Aged 8 months
9 9 4 3
11 13 4 5
7 10 5 4
9 10 5 3
4 4
microscopy.
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Human CFH Transgene Rescues Cfh KnockoutThe ocular and renal phenotypes of 2-year-old C57,Cfh/,
CFH-Y:Cfh/, and CFH-H:Cfh/ mice were studied using
biochemical, histologic, ultrastructural, and ERG methods.
Tissue mRNA and real-time quantitative PCR (qPCR) studies
were conducted on 3-month-old CFH-Y:Cfh/ and CFH-
H:Cfh/ mice. The renal histologic composition was also
investigated in 8-month-old mice of these four genotypes and
CFH-HH:Cfh/mice. The numbers of mice for each class of
experiments are summarized in Table 1.
Genotyping of Mice
Transgenic mouse lines were identiﬁed and maintained by
PCR using DNA isolated from the tail. A human CFH gene
fragment was ampliﬁed using 50-GCAAACCTTTGTTAG-
TAACTTTAG-30 (forward) and 50-GTATTGTGTTCAAA-
TTCTTTTACTG-30 (reverse) primers, resulting in a 550-bp
amplicon. For the Cfh/ sequence, there is an absence of
the 462-bp product ampliﬁed in the normal C57 using
50-GCTACCTACAAATGCCGCCCTG-30 (forward) and
50-TCCAACTGCCAGCCTAAAGGAC-30 (reverse) primers
and the presence of a 200-bp amplicon with 50-GAGGC-
TATTCGGCTATGACTG-30 (forward) and 50-CCACGA-
TAGCCGCGCTGCCTCG-30 (reverse). Primers used to
determine the presence of the rd8 mutation were 50-GCC-
CCTGTTTGCATGGAGGAAACTTGGAAGACAGCTA-
CAGTTCTTCTG-30 (forward) and 50-GCCCCATTTG-
CACACTGATGAC-30 (reverse), which would produce an
amplicon of 244 bp if the mutation was present; using 50-
GTGAAGACAGCTACAGTTCTGATC-30 (forward) with
50-GCCCCATTTGCACACTGATGAC-30 (reverse), no 220-
bp amplicon would be seen if the mutation was present. To
genotype the CFH-HH:Cfh/, CFH-H:Cfh/, and Cfh/
mice obtained through the CFH-H:Cfh/ and CFH-H:Cfh/
crosses, we used a qBiomarker copy number variant PCR assay
(Qiagen Inc., Valencia, CA) speciﬁc for the intron and exon
boundary of exon 2 of CFH to determine the relative genomic
copy number of CFH. qPCR reactions were run in duplicate
(iCycler; Bio-Rad Laboratories, Hercules, CA) at 95C for 10
minutes, followed by 40 cycles at 95C for 15 seconds and
60C for 60 seconds (qBiomarker SYBR ﬂuor mastermix;
Qiagen Inc.). Genomic CFH copies were normalized to mouse
Gapdh (RT2 PCR primer set Gapdh; Qiagen Inc.) using the
2DDCT method.24 CFH-HH:Cfh/ mice have approximately
twice the number of genomicCFH copies comparedwithCFH-
H:Cfh/ mice (Supplemental Figure S1).
Quantitative RT-PCR
Mice were euthanized with carbon dioxide. Brain, eye, in-
testine, heart, kidney, liver, lung, gut, and spleen were
collected from three CFH-Y:Cfh/ and three CFH-H:Cfh/
mice. Total RNA was extracted using an RNeasy lipid tissue
mini kit (Qiagen Inc.) according to the manufacturer’s in-
structions. cDNA was synthesized from total RNA
(SuperScript VILO cDNA synthesis kit; Invitrogen, GrandThe American Journal of Pathology - ajp.amjpathol.orgIsland, NY). qPCR reactions were run in triplicate (iCycler) at
95C for 3 minutes, followed by 40 cycles at 95C for 10
seconds and 60C for 20 seconds, then 72C for 15 seconds
(EXPRESS SYBR GreenER qPCR supermix universal kit;
Invitrogen). Each reaction contained 25 ng of cDNA, 200
nmol/L each primer, and 10 mL of qPCR supermix in 25 mL
of total volume. Relative CFH mRNA expression was
normalized to an endogenous reference gene, GAPDH, for
each tissue using the quantitative 2DDCT method.24 The
primers used were 50-TGTGAGGGTGGTTTCAGGAT-30
(forward) and 50-CCATGAGAAATCTCAGGTGGA-30
(reverse) for CFH and 50-AGGTCGGTGTGAACGGAT-
TTG-30 (forward) and 50-TGTAGACCATGTAGTTGAGG-
TCA-30 (reverse) for GAPDH.
Western Blot Analysis for Quantitation of CFH, C3, C3b,
and FB in Plasma and Tissue Lysates
Mice were euthanized with carbon dioxide, the chest was
cut open, and blood was collected from the heart into EDTA
tubes (BD Microtainer; BD Biosciences, Franklin Lakes,
NJ) at 4C. Tubes were centrifuged for 5 minutes at 1500
rpm, and plasma was collected. RPE/choroid/sclera was
dissected from each mouse eye. Radioimmunoprecipitation
assay buffer (80 mL) with protease inhibitors (cOmplete,
mini, EDTA-free; Roche Diagnostics GmbH, Mannheim,
Germany) was added to each eyecup and was homogenized
using a battery-operated microgrinder from Argos Tech-
nologies (Elgin, IL). After sitting on ice for 30 minutes with
vortexing every 10 minutes, the lysates were centrifuged at
14,000 rpm for 15 minutes at 4C, and the supernatant was
transferred to a new tube. Protein estimation was performed
using a bicinchoninic acid protein assay kit (Pierce
Biotechnology, Rockford, IL), and 5 mg of total protein for
CFH and 20 mg of total protein for C3 and FB were used for
Western blot analyses.
The polyclonal goat anti-human CFH antibody (Quidel
Corp., San Diego, CA) recognized human and mouse CFH
with signiﬁcantly different afﬁnity. Therefore, mouse CFH
standards were prepared by purifying CFH from C57
plasma, as previously described, and were quantiﬁed using
human CFH standards (CompTech, Tyler, TX) on
Coomassie-stained gels using a standard curve of 100 to
600 ng of CFH per well.25 We also established that the
antibody identically recognized human CFH-H and CFH-Y
puriﬁed from human plasma (obtained from homozygous
individuals) and mouse plasma of CFH-Y:Cfh/ and
CFH-H:Cfh/ mice. We quantiﬁed the isolated human
CFH from these sources on Coomasie-stained gels and
compared 8, 32, and 64 pg of each CFH on a Western blot
analysis (Supplemental Figure S2). Protein levels of mouse
CFH in mouse plasma were measured using mouse CFH
standards that were loaded onto the gels with C57 plasma,
and human CFH standards were loaded onto the gels
measuring the human CFH concentration in the CFH-
Y:Cfh/ and CFH-H:Cfh/ mouse plasma. Plasma31
Ding et alsamples were diluted 1:500 in 5% sample buffer, then
1.5 mL of this dilution for CFH and 20 mL for C3, C3b, and
FB were run, nonreduced on 10% Bis-Tris Criterion XT
gels in a 3-(N-morpholino)propanesulfonic acid (MOPS)
buffer, transferred to nitrocellulose, blocked with 10%
nonfat milk for C3 or 4% bovine serum albumin for CFH
and FB, then probed with goat anti-CFH, anti-FB (Kent
Laboratories, Bellingham, WA), or rabbit anti-C3d (Dako,
Carpinteria, CA). Subsequent incubation with horseradish
peroxidaseeconjugated anti-goat or anti-rabbit secondary
antibodies (Jackson ImmunoResearch Laboratories, West
Grove, PA) was followed by detection with ECL Plus re-
agent (Pierce Biotechnology). The images were scanned
and the densities measured by ImageJ software version
1.46 (NIH, Bethesda, MD).
Hemolytic Assay for the Functional Measurement of
Complement Activity in Mouse Plasma
Normally, the functional activity of complement is
measured by the CH50 hemolytic assay. However, because
of the small volumes of mouse blood and the low CH50
values obtained, this assay is difﬁcult to perform on mouse
plasma. The assay described herein measures functional,
intact mouse C3 based on the ability of mouse plasma to
provide C3 to reconstitute C3-depleted human serum in the
lysis of antibody-sensitized sheep erythrocytes.
Preparation of Sensitized Sheep Erythrocytes
To sheep erythrocytes (EAs; Lampire Biological Products,
Pipersville, PA) at 1 109/mL in GVBSþþ (Veronal-buffered
saline, 0.1% gelatin, 0.15 mmol/L CaCl2, and 1.0 mmol/L
MgCl2) was added an equal volume of diluted rabbit anti-
sheep erythrocyte IgG, incubated at 30C for 15 minutes,
then centrifuged and washed in GVBSþþ.
C3 Hemolytic Activity
Keeping everything on ice, six doubling dilutions of mouse
plasma were made in GVBSþþ starting with 1:20 for Cfh/,
CFH-Y:Cfh/, and CFH-H:Cfh/ mouse plasma and 1:50
for C57 mouse plasma. Two hundred microliters of each
dilution was added to EAs (1  108) in 200 mL of GVBSþþ,
then 100 mL of a 1:20 dilution of C3-depleted human serum
was added. The reaction mixture was incubated at 37C in a
shaking water bath for 1 hour, then 500 mL of ice-cold
EDTA-GVBS was added to stop the reaction. The tubes
were spun at 3000 rpm for 5 minutes, and OD was measured
at 412 nm. The reciprocal of the dilution at which 50% he-
molysis was achieved gave the hemolytic units for that
sample. One hundred percent hemolysis was determined by
EAs (1  108) in 200 mL of GVBSþþ with 300 mL of H2O
minus the hemolysis due to EAs (1  108) in 200 mL of
GVBSþþ plus 100 mL of a 1:20 dilution of C3-depleted
human serum plus 200 mL of GVBSþþ.32Immunoﬂuorescence
Mice were deeply anesthetized using a ketamine and xyla-
zine mixture and were perfused transcardially with
phosphate-buffered saline brieﬂy, followed by 4% para-
formaldehyde in 0.1 mol/L phosphate buffer (PB), pH 7.4.
Eyes and kidneys were postﬁxed in the same ﬁxative
overnight and were cut using a vibratome into approxi-
mately 50-mm-thick sections. Free-ﬂoating sections were
blocked with 10% normal donkey serum and then were
incubated overnight with the following primary antibodies:
goat anti-human CFH (dilution 1:100) (A312; Quidel
Corp.) or goat anti-mouse C3 (dilution 1:500) (#55444; MP
Biomedicals, Santa Ana, CA), followed by Alexa Fluore
conjugated donkey anti-goat secondary antibody (dilution
1:500) (Invitrogen) and Hoechst 33258 (Invitrogen) to
counterstain the nuclei. Tyramide signal ampliﬁcation was
used for rat anti-mouse C3b/iC3b/C3c antibody (clone 2/11;
Hycult Biotech, Uden, the Netherlands) to enhance the
signal. Images were acquired using a Leica SP5 laser
scanning confocal microscope (Leica Microsystems Inc.,
Buffalo Grove, IL).
ERG
Mice were dark adapted overnight, their pupils were dilated
with 0.5% tropicamide and 1.25% phenylephrine, and they
were anesthetized with a mixture of ketamine (100mg/kg) and
xylazine (10 mg/kg). Scotopic ERGs were recorded using an
Espion E2 system (Diagnosys LLC, Lowell, MA) at ﬂash
intensities of 2.5 105, 5 105, 5 104, 5 103, 0.05,
0.5, 5, 50, and 500 cd$s/m2, as previously described.26,27 Low-
pass frequency ﬁltering of 50 Hz was applied to remove
oscillatory potentials and noise. Amplitudes of b-waves were
calculated from the bottom of the a-wave response to the peak
of the b-wave. The data points from the b-wave stimulus-
response curves were ﬁtted according to a previously pub-
lished equation28 using the least-square ﬁtting procedure in
OriginPro 9.0 software (OriginLab, Northampton, MA).
Retina Histologic Analysis
Mice were deeply anesthetized using a ketamine and xyla-
zine mixture and were perfused transcardially with
phosphate-buffered saline brieﬂy, followed by ﬁxative (2%
paraformaldehyde and 2% glutaraldehyde in 0.1 mol/L PB,
pH 7.4). Eyes were enucleated and ﬁxed in the same ﬁxative
overnight. Posterior eyes were osmicated, dehydrated
through graded ethanol, inﬁltrated, and embedded in a
mixture of epoxy and Spurr resins. Semithin sections of 0.5
mm were cut, mounted, and stained with toluidine blue.
Sections were viewed and photographed under a light mi-
croscope (Carl Zeiss MicroImaging GmbH, Jena, Ger-
many). The outer nuclear layer (ONL) thickness was
measured along the superior-inferior meridian of the eye at
the level of the optic nerve using ImageJ software.ajp.amjpathol.org - The American Journal of Pathology
Figure 1 Human CFH gene and CFH protein are expressed in mouse tissue. A: Relative expression of CFH to GAPDH was calculated using 2DDCT. CFH mRNA
was widely expressed, with the highest expression in the liver, followed by the spleen, eye, and brain. B: CFH immunoblots quantifying CFH in mouse plasma.
Standard curve of puriﬁed human CFH and human CFH protein in CFH-Y:Cfh/ and CFH-H:Cfh/ mouse plasmas using anti-human CFH antibody. Two mi-
croliters of a 1:1000 dilution of plasma per well. The same antibody also detected mouse CFH protein in C56Bl/6J (C57) mouse plasma. Note that the afﬁnity is
much lower for mouse CFH. C: Plasma CFH protein concentrations calculated from Western blots shown in B. The circulating concentration of human CFH is
much lower compared with that of C57 mouse CFH levels (n Z 3 per genotype). The result was conﬁrmed in three separate experiments. D: Immunoﬂuo-
rescence localization of CFH on retinal pigment epithelium (RPE)/choroid sections of 2-year-old mice. Strong labeling of CFH is found in the choriocapillaris of
C57 eye. Staining is absent in Cfh/ mice. Weak staining is present in the choriocapillaris of CFH-Y:Cfh/ and CFH-H:Cfh/ mice. Puncta inside the RPE are
lipofuscin autoﬂuorescence. Data are given as means  SD. Scale bar Z 20 mm. OS, outer segment.
Human CFH Transgene Rescues Cfh KnockoutRetina TEM and Basal Deposit Sampling
For transmission electron microscopy (TEM), approxi-
mately 200-mm-thick vibratome sections in the center of the
eye through the optic nerve head were osmicated, stained en
bloc with uranyl acetate, dehydrated, and embedded in a
mixture of epoxy and Spurr resins. Each embedded section
was then divided into two parts on each side of the optic
nerve head (Supplemental Figure S3A). Thin sections of 60
to 80 nmwere cut from each region spanning 70% to 80% of
the total length of the retina from the optic nerve toward the
ora serrata, collected onto 400-mesh thin-bar copper grids
(T400-Cu; Electron Microscopy Sciences, Hatﬁeld, PA),
and stained with uranyl acetate and Sato’s lead. Sections
were viewed using a Tecnai G2 electron microscope (FEI,
Hillsboro, OR). Images containing the basal RPE and BrM
were taken on the parts of the section adjacent to the grid’s
bar throughout the length of the retina. For each image, the
thickness of the deposits was measured from the central
elastin layer of the BrM to the top of the deposit near the
edges of the image (Supplemental Figure S3) using ImageJ
software. Cumulative distribution of deposit thickness was
plotted using OriginPro 9.0 software. A nonparametric
Kolmogorov-Smirnov test was used to compare the differ-
ences between the distribution curves.
Kidney Histologic Analysis and Glomerular Grading
Kidneys from 2% paraformaldehydee and 2% gluta-
raldehydeeperfused mice were postﬁxed overnight in theThe American Journal of Pathology - ajp.amjpathol.orgsame ﬁxative before being dehydrated and embedded in
parafﬁn. Ten-micron sections were cut and stained with peri-
odic acideSchiff reagent. Glomerular histologic appearance
was graded using the grading system described previously21 in
which grade 0 was normal; grade I, segmental hypercellularity
in 10% to 25% of the glomeruli; grade II, hypercellularity
involving>50% of the glomerular tuft in>25% to 50% of the
glomeruli; grade III, hypercellularity involving >50% of the
glomerular tuft in >50% to 75% of the glomeruli; and grade
IV (the most severe), glomerular hypercellularity in >75% or
crescents in>25% of the glomeruli. For scoring, 50 glomeruli
per section were analyzed by masked investigators (J.-D.D.,
C.M.). Semithin plastic sections and TEM sections were
processed the same way as the retina tissue.
Results
Generating Human CFH Transgenic Mice
We generated nine founder transgenic mice using full-length
BACs containing the Y402 (n Z 5) and H402 (n Z 4)
variants of human CFH. These founders were then crossed to
C57 mice. Germline transmission was conﬁrmed in all
founder lines by analyzing the genomic DNA of the N1
offspring. However, mRNA for human CFH was found in
only seven lines (ﬁve for H402 and two for Y402). These
seven lines were then crossed to Cfh/ mice.21 Using qPCR
analysis, we observed the highest levels of human CFH
mRNA in the liver, although other tissues, including the eye,
also express the transcript (Figure 1A).33
Figure 2 Human CFH protein inhibits activation of the mouse AP of the complement system in vivo. A: Mouse plasma hemolytic C3 activity. The C57
mouse had the highest hemolytic activity, whereas no hemolysis was detected using Cfh/ mouse plasma. CFH-Y:Cfh/ and CFH-H:Cfh/ mice had
approximately 30% and 15%, respectively, of the C57 hemolytic activity. B: Western blot analysis of C3 in the plasma. All the C3 in C57 mice was
uncleaved. CFH-Y:Cfh/ and CFH-H:Cfh/ mice showed approximately equal amounts of C3 and C3b, although there was signiﬁcantly more of both in
CFH-Y:Cfh/ mice, and only C3b could be readily detected in Cfh/ mice. C: Western blot analysis of C3 in the RPE/BrM/choroid/sclera. There was a
smaller difference in the relative amounts of C3 and C3b between the genotypes in the tissue, and a small amount of intact C3 was detected in Cfh/
mice, suggesting that inhibitors other than CFH act on locally produced C3. FB levels in plasma (D) and in the RPE/choroid/sclera (E) are shown.
Western blot analysis of FB in plasma and tissue showing that virtually all the FB has been consumed in the plasma and tissue in Cfh/ mice, whereas
there is some intact FB in CFH-Y:Cfh/ and CFH-H:Cfh/ mice, although this is signiﬁcantly less than that found in C57 mice. F: Confocal immu-
noﬂuorescence images depict immunolocalization of C3b/iC3b/C3c (green) in mouse eyes. In C57 mice, C3b/iC3b/C3c immunolabeling was present in
dense patches along the basal side of the retinal pigment epithelium (RPE)/BrM and in the choriocapillaris. Immunolabeling for C3b/iC3b/C3c was
totally absent in Cfh/ mice. In CFH-Y:Cfh/ and CFH-H:Cfh/ retinas, C3b/iC3b/C3c staining was seen only in the choriocapillaris. Data are given as
means  SD. Scale bar Z 20 mm. OS, outer segment.
Ding et alSigniﬁcant amounts of human CFH protein could be
detected in the plasma of only two of the lines crossed to
Cfh/ mice, one expressing the H402 form (CFH-H:Cfh/)
and the other the Y402 form (CFH-Y:Cfh/). We
conﬁrmed the amino acid identity at position 402 in these
mice by matrix assisted laser desorption ionization tandem
time-of-ﬂight analyzer (MALDI-TOF-TOF) as previously
described.29 Quantiﬁcation of means  SD CFH concen-
trations in these two mouse lines revealed that there is
twofold more CFH protein in CFH-Y:Cfh/ plasma
(20.3  5.8 mg/mL) than in CFH-H:Cfh/ plasma
(9.2  3.5 mg/mL; P < 0.001) (Figure 1, B and C). For
comparison, the means  SD plasma concentration of
mouse CFH protein in C57 mice is 209  47 mg/mL, 10 to
20 times higher than human CFH in the transgenic lines
(Figure 1, B and C). In the back of the eye, CFH mainly
localized to the choriocapillaris, as shown by immunoﬂuo-
rescence (Figure 1D). Staining is strong in C57 mice but
weaker in CFH transgenic mice. Staining was absent in
Cfh/ mice (Figure 1D).34Human CFH Interacts with the Mouse AP
To address whether the human CFH protein can substitute for
the mouse CFH and regulate the mouse AP, we tested the
impact of human CFH expression on inhibition of the
cleavage of C3 in vivo. We developed a sensitive and
quantitative hemolytic assay for the measurement of intact,
fully functional C3 in mouse serum. The means  SD C3
hemolytic activity in C57 mouse serum was 369  83 U/mL
but was not detectable in theCfh/mouse, indicating that all
the C3 in the Cfh/ mice was already cleaved (Figure 2A).
Means SD hemolysis was readily measured in the serum of
the two humanized CFH mouse lines (CFH-Y:Cfh/:
108  32; CFH-H:Cfh/: 60  19), demonstrating that
human CFH inhibits C3 cleavage (Figure 2A). The amount of
hemolysis measured in CFH-Y:Cfh/ mice was signiﬁ-
cantly higher than in CFH-H:Cfh/ animals (P < 0.001;
Student’s t-test), consistent with the higher level of CFH
expression in CFH-Y:Cfh/ mice. Western blot analyses of
C3 in plasma from Cfh/ mice conﬁrmed the absence ofajp.amjpathol.org - The American Journal of Pathology
Figure 3 The human CFH transgene partially rescues the visual
function loss caused by the Cfh gene deletion. A: Representative traces
of the scotopic ERG ﬂash response. B: Scotopic ERG ﬂash responses.
Stimulus-response curves of b-wave amplitudes. Baseline ERGs obtained
from normal C57BL/6J (C57) controls (black) and affected Cfh/ ani-
mals (pink). The scotopic ERG b-wave amplitudes were partially pre-
served in CFH-Y:Cfh/ mice but not in CFH-H:Cfh/ mice. Data are
given as means  SEM. *P < 0.05, **P < 0.01 (Student’s t-test)
compared with Cfh/ animals.
Figure 4 The human CFH transgene protects against photoreceptor loss
caused by the Cfh gene knockout. A: Representative micrographs of the retina
of the four mouse lines. B: The plot of ONL thickness versus eccentricity (spider
plot) from the optic nerve shows that the ONL in the C57 retina was signiﬁ-
cantly thicker than the Cfh/ ONL. The CFH-Y:Cfh/ ONL was also thicker
than the Cfh/ ONL, indicating that photoreceptor degeneration is partially
protected. There was a slightly thicker ONL of CFH-H:Cfh/mice in the inferior
region. Data are given as means  SEM. *P < 0.05, **P < 0.01, and
***P < 0.001 (Student t-test). Scale barZ 50 mm. GCL, ganglion cell layer;
INL, inner nuclear layer; IPL, inner plexiform layer; IS, inner segment; ONL,
outer nuclear layer; OPL, outer plexiform layer; OS, outer segment; RPE, retinal
pigment epithelium.
Human CFH Transgene Rescues Cfh Knockoutdetectable intact C3, with only the lower C3b band being
present (Figure 2B).
Human CFH inhibition of C3 hydrolysis in vivo was also
observed in the RPE/choroid/sclera tissue by Western blot
analysis. Two tightly migrating bands were identiﬁed on the
blot as C3 and C3b. The amounts of C3 and C3b were
greatly reduced in Cfh/ mice compared with C57 mice,
but not completely absent, suggesting that inhibitors other
than CFH are acting at the tissue level. In CFH-Y:Cfh/
and CFH-H:Cfh/ RPE/choroid/sclera, the levels of C3
and C3b were higher than those in Cfh/ mice, demon-
strating that human CFH has an inhibitory effect at the
tissue site (Figure 2C).
We also measured the amount of FB in the plasma
(Figure 2D) and the RPE/choroid/sclera (Figure 2E) of
CFH-Y:Cfh/, CFH-H:Cfh/, and Cfh/ mice. On
activation of the AP, FB binds to C3b and is subsequently
cleaved by complement factor D to form the AP convertase
C3bBb. Compared with C57 mice, FB in Cfh/ mice was
nearly completely consumed as a result of uncontrolled
activation of the AP. In contrast, FB levels were partially
restored in humanized mice, indicating that AP activation
was comparatively inhibited (Figure 2, D and E).The American Journal of Pathology - ajp.amjpathol.orgImmunoﬂuorescence of C3b/iC3b/C3c on retina sec-
tions was consistent with the biochemical results. In C57
mice, C3b/iC3b/C3c immunolabeling was detected in
dense patches along the basal RPE/BrM and in the35
Ding et alchoriocapillaris. Immunolabeling for C3b was totally
absent in Cfh/ mice. In CFH-Y:Cfh/ and CFH-
H:Cfh/ retinas, weaker C3b/iC3b/C3c staining was
present in the choriocapillaris but not in the basal RPE/
BrM (Figure 2F).
Human CFH Partially Restores Retinal Visual Function
and Inhibits Photoreceptor Loss
We next assessed visual function of the retinas of these mice
using scotopic ERG, which primarily represents rod
photoreceptor function.30 As previously reported,19 the
b-wave of Cfh/ mice was substantially attenuated
compared with that of C57 mice as the ﬂash intensity
increased (Figure 3). The b-wave of CFH-Y:Cfh/ mice
was signiﬁcantly larger than that of Cfh/ mice (P < 0.05),
particularly at higher stimulus intensities. In contrast, we
were unable to detect a statistically signiﬁcant rescue in the
b-wave of CFH-H:Cfh/ mice (Figure 3).
To determine whether the visual function deﬁcit in these
mice could be attributed to photoreceptor loss, we evaluated
the retina structure on semithin plastic sections. WeFigure 5 Expression of human CFH reduces the deposit load. A: Representative
mouse genotypes. The genotype with the least amount of deposits is represented b
trace) compared with the curve that is furthest to the right (CFH-H:Cfh/; blue
thickness was distributed over a large range for all four genotypes, but C57 mice h
mice had signiﬁcantly more deposits than C57 mice (median thickness, 658 nm).
C57 curve, demonstrating that these mice have similar amounts of basal deposits a
the right of the Cfh/ curve, shows that these mice had statistically signiﬁ
nonparametric Kolmogorov-Smirnov test was used to compare the differences bet
CFH-Y:Cfh/ mice overall had fewer deposits than Cfh/ mice, whereas CFH-
**P < 0.01, ***P < 0.001 (two-sample t-test). Scale bar Z 1 mm.
36measured the extent of photoreceptor loss using measure-
ments of ONL thickness as a function of retinal position
along the superior-inferior meridian of the eye at the level of
the optic nerve (Figure 4). Compared with the control C57
retina, there was an approximately 25% reduction in
ONL thickness in the Cfh/ retina. The ONL of the
CFH-Y:Cfh/ retina was signiﬁcantly thicker than that of
the Cfh/ retina. In contrast, CFH-H:Cfh/ ONL thick-
ness showed only a slight increase over the Cfh/ retina in
the inferior portion (Figure 4). This histologic analysis
suggests that attenuation of the ERGs, relative to the wild
type, is most likely a reﬂection of the photoreceptor loss in
the transgenic mice.
Human CFH Reduces the Amount of Sub-RPE Deposits
As mice age, debris accumulates between the RPE and the
BrM as sub-RPE basal deposits, similar in composition to
deposits seen in early AMD. We found substantial amounts
of sub-RPE deposits in aged mice of all four genotypes
(Figure 5). Unlike basal deposits in human tissue,31 clear
structural distinctions between basal linear depositsTEM images of basal deposits. B: Distribution of basal deposits for the four
y the curve that is furthest left (closest to the y axis) in the plot (C57; black
trace) with the greatest amount of sub-RPE deposits overall. The deposit
ad the least amount of basal deposits (median thickness, 321 nm). Cfh/
The curve representing the deposit thickness in CFH-Y:Cfh/ is close to the
s C57 mice (median thickness, 540 nm). The CFH-H:Cfh/ curve, which is to
cantly more deposits than Cfh/ mice (median thickness, 763 nm). A
ween the deposit distribution curves. C: The thickness of deposits. C57 and
H:Cfh/ mice had the most deposits. Data are given as means  SEM.
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Human CFH Transgene Rescues Cfh Knockout(deposits within the inner collagenous layer of the BrM) and
basal laminar deposits (deposits between the basal lamina of
the RPE and the basal infoldings) could not be detected in
mice. In fact, basal laminar deposits seemed to be the pre-
dominant form in the mice. The deposits usually had a
nodular appearance, extending from the basal lamina into
the spaces between the basal infoldings of the RPE.
Electron-dense multilayer membranous structures of 50 to
200 nm across were frequent between nodules of deposits
(Supplemental Figure S4A). These structures resembled
the “membranous debris” found in the human drusen.32
We did not notice an obvious association between the
presence of the membranous debris or the long-spacing
collagens and a distinct mouse genotype. The deposits
were primarily amorphous, although long-spacing colla-
gens were found in some deposits (Supplemental
Figure S4B). We quantitatively measured the deposit
load in the different mice to determine whether there was
an increase in the amount of deposit in any of the mouse
lines (Figure 5). We deﬁned the thickness of deposits as
the distance between the central elastin layer of the BrM
and the basal surface of the RPE, which included basal
linear and basal laminar deposits but excluded the outer
collagenous layer of the BrM (Supplemental Figure S4A).
The thickness of the outer collagenous layer varies
depending on its spatial relationship to a nearby pillar ofFigure 6 The human CFH transgene rescues kidney damage in Cfh/ mice. A
year-old C57 mice showed mild age-related damage, including mild thickening
mice, the glomerular basement membrane (GBM) was severely thickened (arrow
The structure of the CFH-Y:Cfh/ glomerulus was similar to that of C57 mice, i
glomeruli of the CFH-H:Cfh/ kidneys do not show any improvement. B: Repres
signiﬁcant thickening of the GBM and expansion of the mesangial matrix. Sca
nucleus; PN, podocyte nucleus; US, urinary space.
The American Journal of Pathology - ajp.amjpathol.orgthe choriocapillaris, but it has not been correlated to basal
deposits on the RPE side of the BrM. We found that for a
given retina section, the thickness of deposits varied from
approximately 200 nm (no deposits) up to 4 mm (many
deposits). Overall, the thickness of deposits fairly
randomly distributed over the retina except where it ap-
pears to taper off nearer the ora serrata. However, in some
places the thickness changes abruptly (Supplemental
Figure S4, CeF). Therefore, rather than estimating the
amount of sub-RPE deposits per eye by examining a few
TEM images at random places, we developed a method to
systematically sample and measure the thickness of sub-
RPE deposits using TEM (Supplemental Figure S3;
detailed in Materials and Methods). Using this sampling
method, a means  SD of 61  8 images were taken per
retina, covering nearly the entire length of a retina.
We graphed the distribution of deposit thickness on a
cumulative frequency plot (Figure 5). The curve that is
furthest left (closest to the y axis) in the plot represents the
genotype with the least amount of deposits (C57, black
trace) compared with the curve that is furthest to the right
(CFH-H:Cfh/, blue trace) with the greatest amount of
sub-RPE deposits overall (Figure 5B). The most deposits
were found in CFH-H:Cfh/ mouse eyes. The curve for
the CFH-H:Cfh/deposit measurements falls to the right of
the Cfh/ curve, showing that these mice had statistically: Periodic acideSchiffestained sections of mouse kidney glomeruli. Two-
of the GBM and expansion of the mesangial matrix (asterisks). In Cfh/
heads), and the mesangial matrix was signiﬁcantly expanded (asterisks).
llustrating the protective effect of the CFH-Y transgene. In contrast, the
entative TEM images. Glomeruli of Cfh/ and CFH-H:Cfh/ mice showed
le bars: 20 mm (A); 2 mm (B). CL, capillary lumen; EN, endothelial cell
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Table 2 Grading of 2-Year-Old Mouse Glomerulus Pathology by
Histology
C57 Cfh/ CFH-Y:Cfh/ CFH-H:Cfh/
ID Grade ID Grade ID Grade ID Grade
1685 I 1549 IV 1501 I 1500 III
1686 II 1550 IV 1502 I 1547 IV
1687 II 1689 IV 1503 I 1548 IV
1688 I 1690 IV 1695 I 1693 III
1596 I 1694 III
The glomeruli of C57 and CFH-Y:Cfh/ mice had similar mild histologic
damage (not signiﬁcant; Mann-Whitney U-test), whereas the Cfh/ and
CFH-H:Cfh/ glomeruli were severely damaged compared with C57
(P < 0.05).
Ding et alsigniﬁcantly more deposits than Cfh/ mice (median
thickness, 763 nm). A nonparametric Kolmogorov-Smirnov
test was used to compare the differences between the
deposit distribution curves and for analysis of mean deposit
thickness, which showed the same statistically signiﬁcant
differences (Student’s t-test) (Figure 5C).
Human CFH Rescues the Renal Damage in Cfh/ Mice
In addition to structural and functional abnormalities in the
eye, Cfh/ mice also spontaneously develop DDD. This has
been attributed to uncontrolled C3 activation in these Cfh/
mice.21 If human CFH can inhibit mouse C3 tick-over, thenwe
expect the kidney damage due to the Cfh knockout to be
protected by the human protein. Thus, we examined the kidney
morphology of these four lines of mice. Periodic acide
Schiffestained kidney sections of 2-year-old C57 mice
showed mild damage to the glomeruli, including slight
thickening of the glomerular basement membrane (GBM) and
minor expansion of the mesangial matrix (Figure 6A). Such
age-related damage has been reported previously.33 InFigure 7 C3 and the activated fragment of C3, C3b/iC3b/C3c, immunoﬂuo
prominent in the glomeruli of Cfh/ and CFH-H:Cfh/ mice but negligible in C
38contrast, there was much more severe damage to the glomeruli
of Cfh/ mouse kidneys, including thickening of the GBM,
mesangial matrix expansion, and hypercellularity. These
pathologic changes seen in Cfh/ mice were absent in CFH-
Y:Cfh/ mice but could still be seen in CFH-H:Cfh/ mice
(Figure 6A). We also conﬁrmed these phenotypes at the ul-
trastructural level (Figure 6B).
To quantify the histopathologic changes observed in the
kidney, we analyzed periodic acideSchiffestained sections
using a previously published grading method21 in which
grade 0 corresponds to normal and grade IV to most
severely damaged (see Materials and Methods for details).
The glomerular histology of C57 mice scored grades I and
II, reﬂecting mild damage due to normal aging (Table 2).
The glomeruli of Cfh/ mice all scored grade IV,
indicating the most severe damage. The glomeruli of CFH-
Y:Cfh/ mice all scored grade I, suggesting that the DDD-
like pathology was inhibited by expression of the human
CFH protein. However, the glomeruli in the kidneys of
CFH-H:Cfh/ mice did not show signiﬁcant improvement
compared with those of Cfh/ mice (Table 2). The dif-
ference in rescue of the Cfh/ kidney phenotype between
CFH-Y:Cfh/ and CFH-H:Cfh/ mice suggests that there
is a threshold concentration of CFH required to protect the
kidney from damage, which was not reached in CFH-
H:Cfh/ mice, or that Y402 CFH is more effective at
protecting the kidney than H402 CFH.
To further investigate whether the protective effect of CFH
expression in CFH-Y:Cfh/mice was due to the inhibition of
complement activation in the glomeruli by the human CFH,
we immunostained for C3 and the activated C3 fragment C3b/
iC3b/C3c on kidney sections (Figure 7). As expected, neither
C3 nor C3b/iC3b/C3c immunolabeling was detected in C57
glomeruli, whereas immunolabeling for both was prominent in
Cfh/ glomeruli. The immunoﬂuorescence signals in therescence in mouse glomeruli. C3 and C3b/iC3b/C3c immunolabeling was
57 and CFH-Y:Cfh/ renal tissue. Scale bar Z 50 mm.
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Human CFH Transgene Rescues Cfh Knockoutglomeruli of CFH-Y:Cfh/ mice were barely detectable,
implying that C3 activation was inhibited. However, there
were still strong C3b/iC3b/C3c labeling in the glomeruli of
CFH-H:Cfh/ mice (Figure 7).
Dose-Dependent Effects of Human CFH
So far, the results suggest that the human CFH transgene
protected the retinal and renal damage in CFH-Y:Cfh/ mice,
but the effects were marginal or nil in CFH-H:Cfh/ mice.
Because the concentration of CFH in CFH-Y:Cfh/ mice is
twice that inCFH-H:Cfh/mice, it is impossible to determine
whether rescue of the Cfh/ phenotype in CFH-Y:Cfh/
mice was due to the amount of CFH expressed or to the Y402
variant. To address this confounder, we mated CFH-H:Cfh/
mice together to generate a line of homozygous CFH-H
transgenic mice (CFH-HH:Cfh/). Quantiﬁcation of circu-
lating CFH levels in CFH-HH:Cfh/ mice revealed similar
levels of CFH as CFH-Y:Cfh/ mice (Supplemental
Figure S5A). In addition, activation of the AP as measured
by C3 breakdown was similar between CFH-HH:Cfh/ and
CFH-Y:Cfh/ mice (Supplemental Figure S5B), and CFH-
HH:Cfh/ mice have the same level of hemolytic activity as
CFH-Y:Cfh/ mice (Supplemental Figure S5C).
The oldest homozygous mice examined were 8 months old
at the time of the study, and they did not seem to have any
obvious developmental or other abnormalities. We analyzed
the retina and kidney morphology of 8-month-old mice of all
the genotypes. Contrary to a previous report,34 we did not
detect any morphologic differences on semithin plastic sec-
tions between C57 andCfh/mouse retinas at this age, which
is consistent with the late onset of pathologic abnormalities in
AMD. On the other hand, the DDD-like renal damage is
detectable at this age in Cfh/ mice (Table 3).21 In 8-month-
old CFH-Y:Cfh/ and CFH-HH:Cfh/ mice, the glomeruli
were normal, whereas CFH-H:Cfh/mouse kidneys showed
some damage but not to the extent detected in age-matched
Cfh/ mice (Table 3). These results demonstrate that in the
kidney, the protective effects can be explained by the elevated
concentration of the human CFH protein rather than the po-









ID Grade ID Grade ID Grade ID Grade ID Grade
1867 0 1870 III 1872 I 1878 II 1882 I
1868 I 1871 II 1873 0 1879 III 1883 I
1689 0 1874 III 1875 II 1881 I 1884 0
1877 II 1876 0 1885 I
1880 IV
The glomeruli of C57, CFH-Y:Cfh/, and CFH-HH:Cfh/ mice were normal
at 8 months, whereas the Cfh/ and CFH-H:Cfh/ glomeruli were
damaged compared with C57 (P < 0.05).
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AMD and DDD share the H402 at-risk genotype as well as
overt pathologic similarities supporting the existence of a
genotype-phenotype relationship.14 We generated trans-
genic mice that express the normal or risk-associated vari-
ants of the full-length human CFH protein. For the ﬁrst time,
we show that human CFH prevents the retina and kidney
damage caused by Cfh deletion in a dose-dependent manner
and that human CFH can inhibit the mouse AP of the
complement system in vivo.
CFH is a large soluble glycoprotein of 155 kDa that
consists of 20 short consensus repeats (SCR). The H402
variant associated with risk of AMD and DDD is located in
SCR7. Previously, transgenic mice expressing a chimeric
CFH, in which the human CFH sequence for SCR6-8
ﬂanked by mouse sequences SCR1-5 and SCR9-20, were
generated.35 Despite the fact that the chimeric CFH protein
expressed in these animals could restore the C3 serum levels
of Cfh/ mice, they still developed early AMD-like path-
ologic abnormalities at as young as 12 months old, an age at
which the retina of Cfh/ mice is still relatively normal.
Thus, it is possible that the effect of the expressed chimeric
protein is unrelated to modulation of the AP. Expression of
the chimeric protein in these animals is controlled by an
apolipoprotein E promoter.35 Apolipoprotein E is expressed
in the RPE, but it is also expressed by Müller cells in the
neural retina.36 Therefore, it is plausible that the chimeric
CFH produced by Müller cells exerts adverse effects on the
structure and function of the retina unrelated to modulation
of the AP. In contrast, the full-length BACs we used to
create the humanized CFH mice include the endogenous
regulatory elements in the transgene, which allows normal
tissue- and cell-speciﬁc expression of human CFH. This is
especially important in the case of CFH, which is a large,
complex gene with many introns and exons and alternative
splicing. Furthermore, once a gene expression pattern is
recapitulated by a BAC transgene (which we show in the
present study), the regulatory elements that are crucial to
gene regulation, RNA processing, and other operations may
potentially be systematically dissected in a way that is not
possible in humans.37,38
Human and mouse CFH proteins share 61% identity and
70% similarity. Mouse CFH is 1252 amino acids in length
compared with human CFH, which is 1231 amino acids, and
it is less glycosylated than the human form. It was, there-
fore, not self-evident that human CFH could function
properly in the mouse complement system. This study
established that human CFH can, in fact, effectively regulate
the mouse AP. The protection from damage in the eye
associated with Cfh/ in these humanized mice was
directly correlated with the human CFH levels expressed in
each line. These ﬁndings are consistent with a recent pop-
ulation study showing that some AMD patients have
decreased plasma CFH concentrations.39 Still, it cannot be
entirely ruled out that the phenotypic differences we have39
Ding et alseen between CFH-H:Cfh/ and CFH-Y:Cfh/ mice
could be due to the H versus Y amino acid at position 402.
Cells in the RPE/choroid/sclera of C57, CFH-H:Cfh/,
and CFH-Y:Cfh/ mice synthesize C3, CFH, and FB,
whereas Cfh/ mice synthesize C3 and FB. The contribution
in the eye of these locally produced complement proteins
compared with the contribution of complement proteins from
the circulation is not known; however, this study indicates
that there was a smaller difference in the relative amounts of
C3 and C3b between genotypes in the RPE/choroid/sclera. In
fact, a small amount of intact C3 was detected in Cfh/ mice
in the RPE/choroid/sclera, suggesting that inhibitors other
than CFH act on locally produced C3 (Figure 2B). These are
likely to be the membrane-bound inhibitors of complement
(Crry, CD55, and CD46).
Since discovery of the genetic association between CFH
and AMD, one of the major tasks has been to explore the
functional differences between normal Y402 and risk-
associated H402 variants of CFH. A few in vitro studies
using recombinant CFH or fragments containing SCR7 have
reported functional differences between the Y402 and H402
variants.40,41 In contrast, our previous work using full-length
proteins extracted from human plasma demonstrated that the
two variants were indistinguishable in ﬂuid-phase functional
assays.25 These results highlight the complexity of the CFH
molecule and the important differences between native full-
length CFH and recombinant fragments or full-length pro-
teins. For example, dependence on the tertiary structure and
interaction of different regions of the CFH molecule for
binding and activity cannot be entirely replicated by recom-
binant fragments of CFH.
One of the primary purposes of creating humanized CFH
mice was to investigate the functional differences between
the CFH variants in a well-controlled model system. How-
ever, this goal was hampered by the difference in expression
levels of the CFH protein in the two mouse lines. To address
this problem and match the protein levels between the
variants we generated a homozygous CFH-H transgenic
mouse line crossed to the Cfh/, which has twice the
concentration of hemizygous CFH-H:Cfh/ and is, thus,
expressed at levels similar to CFH-Y:Cfh/. Initial analysis
of the kidneys of young mice showed no differences be-
tween CFH-HH:Cfh/ and CFH-Y:Cfh/ mice. In future
studies, we still need to examine the ocular phenotype in
these CFH-HH:Cfh/ mice when they are old enough (2
years) to determine whether their eyes are also similar to
those of CFH-Y:Cfh/ mice because characterizing the
CFH-HH:Cfh/ mice will determine whether the ﬁndings
described herein are solely due to concentration effects or
whether the CFH genotype plays a role in the observed
pathologic abnormality.
We will be particularly interested in analyzing the levels of
the sub-RPE deposit in CFH-HH:Cfh/ mice because unlike
the other ocular phenotypes associated with Cfh/, the
amount of basal deposits in hemizygous CFH-H:Cfh/ mice
were not decreased compared with the amounts in Cfh/ but40rather were increased even more than that inCfh/mice. The
presence of statistically signiﬁcantly thicker sub-RPE deposits
compared with deposits in Cfh/ mice combined with
apparent protection in the neural retina in CFH-H:Cfh/
mice, based on ONL thickness, compared with Cfh/ mice
suggests that the events in neural retina and RPE/choroid are
separable. The H variant of CFH may increase the risk of
AMD by facilitating more sub-RPE deposit formation without
directly contributing to damaging the neural retina.
CFH deﬁciency causes DDD, atypical hemolytic-uremic
syndrome, and other renal diseases. There is no deﬁnitive
therapy for DDD,42 although a single dose of human CFH
injected into Cfh/mice can brieﬂy restore serum C3 levels
and resolve GBM C3 deposition.43 This ﬁnding supported
the use of exogenous human CFH as a potential new therapy
for patients with DDD or atypical hemolytic-uremic syn-
drome associated with CFH deﬁciency. However, preclinical
tests in Cfh/mice with long-term administration of human
CFH were inconclusive as the mice eventually generated
anti-human CFH antibodies that triggered immune complex
glomerulonephritis and renal failure.43 The CFH-H:Cfh/
mice characterized in the present study represent a good
model to test human CFH therapy for DDD because these
mice have detectable levels of human CFH and are, thus,
unlikely to generate anti-human CFH antibodies when
human CFH is administered, but they also still develop the
DDD-like phenotype needed to test potential therapies.
In conclusion, we developed new murine models express-
ing normal and variants of human CFH associated with risk of
AMD and DDD. Analysis of these animals revealed, for the
ﬁrst time, that human CFH can inhibit the mouse AP in vivo. In
addition, we show that human CFH prevents the retina and
kidney damage caused by Cfh deletion in a dose-dependent
manner. The animal models represent valuable tools to study
the mechanisms and environmental contributors of normal and
at-risk human CFH variants in a deﬁned model system.
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